Managing Moderate-to-Severe Psoriasis in the Elderly

被引:0
作者
Nicola Balato
Cataldo Patruno
Maddalena Napolitano
Angela Patrì
Fabio Ayala
Raffaele Scarpa
机构
[1] University of Naples Federico II,Department of Dermatology
[2] University of Naples Federico II,Department of Rheumatology
来源
Drugs & Aging | 2014年 / 31卷
关键词
Psoriasis; Infliximab; Etanercept; Adalimumab; Ustekinumab;
D O I
暂无
中图分类号
学科分类号
摘要
Managing psoriasis in the elderly can be difficult for physicians, who must consider comorbidities, the resulting polypharmacy, and progressive functional impairment of several organs. Indeed, topical agents are the first-line treatment for limited disease. Phototherapy is recommended if topical drugs are not sufficient and the patient has multiple comorbidities and risk factors that make them a poor candidate for an oral or injectable systemic agent. The most important pharmacokinetic alteration in the elderly population is the decreased excretory capacity of the kidney; thus, cyclosporine should be considered a last resort treatment, and the administered dose of methotrexate should be lowered according to the reduction in estimated creatinine clearance. Acitretin can be used in the absence of severe renal insufficiency, paying attention to lipid profile, treating eventual hyperlipidemia, and closely monitoring liver enzymes. Available data on biological drugs in the elderly are limited. Biologics are associated with a small but significant overall risk of infections. However, there is no convincing evidence that the relative risk of infection with anti-tumor necrosis factor (TNF)-α therapy increases with age. Nevertheless, the package inserts for biologics recommend caution when administering these medications to the geriatric population, due to the high baseline risk of infection in such patients. Etanercept seems to be well tolerated, possibly because of its lower immunosuppressive characteristics compared with other biologics. However, studies with larger sample sizes are needed to confirm its safety.
引用
收藏
页码:233 / 238
页数:5
相关论文
共 163 条
  • [1] Ayala F(2007)Clinical presentation of psoriasis Reumatismo 59 40-45
  • [2] Henseler T(1985)Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris J Am Acad Dermatol 13 450-456
  • [3] Christophers E(2011)Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 1-10
  • [4] Mrowietz U(2012)The safety of systemic treatments that can be used for geriatric psoriasis patients: a review Dermatol Res Pract 2012 367475-863
  • [5] Kragballe K(2002)Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options Drugs Aging 19 847-596
  • [6] Reich K(1999)Clinical guidelines: developing guidelines BMJ 318 593-39
  • [7] Spuls P(2005)Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris Eur J Dermatol 15 37-393
  • [8] Griffiths CE(2002)A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris Dermatology 205 389-144
  • [9] Nast A(2012)Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis Cutis 90 140-545
  • [10] Franke J(2011)Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 65 537-178